Canakinumab  (Synonyms: Ilaris; ACZ 885)

Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC₅₀ values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin^[1][2].

Human IgG1(K214R) kappa

Human IgG1 (K214R) kappa, Isotype Control

Human

IL-1b

Canakinumab (0-7 nM) dose dependently represses IL-6 production in marmoset peripheral blood mononuclear cells with IC₅₀s of 43.6 and 40.8 pM for human and marmoset IL-1β^[2]. Canakinumab effectively competes with IL-1RI and IL-1RII for binding to IL-1b^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

3553  [NCBI]

P01584

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

145.5 kDa

914613-48-2

Liquid

Colorless to light yellow

[Canakinumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized IL-1 beta Protein, Human (HY-P7028) can bind Canakinumab. The EC₅₀ for this effect is 6.151 ng/mL.
• 
  Flow cytometric analysis of 1.5X10⁶ RAW264.7 cells treated with 50 nM phorbol-12-myristate-13-acetate (PMA, HY-18739) and 5 μg/ml lipopolysaccharide (LPS, HY-D1056) for 24 hours with Canakinumab (HY-108810, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃, Human IgG1 kappa, Isotype Control (HY-P99001, blue) was used as the isotype control.

• [1]. Dhimolea E. Canakinumab. MAbs. Epub 2010 Jan 15.  [Content Brief]

  [2]. Rondeau JM, et al. The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β. MAbs. 2015;7(6):1151-60.  [Content Brief]